A&G Pharmaceutical, Inc. announced that it has received an equity investment from Olympus Corporation
Columbia, MD, and Tokyo, Japan, August 31, 2007—Proceeds from the financing will be used to help the commercial launch of A&G’s GP88 Biopsy Staining Kit for breast cancer and support development of A&G’s blood test for breast cancer, based on the same GP88 biomarker.
“We are delighted to partner with Olympus, a company with a world-class reputation in digital cameras, clinical analyzers, early detection of cancer through endoscopes and high-end microscopes for pathologists and other researchers,” said Ginette Serrero, PhD, CEO of A&G.
About A&G Pharmaceutical
A&G Pharmaceutical is a theranostics company creating and developing monoclonal
antibodies to cancer-specific targets as a basis for novel therapeutic and
diagnostic products. A&G’s therapeutics division is pursuing development
of anti-GP88 and other monoclonal antibody drugs for cancer. On the diagnostics
side, A&G is currently developing test kits that will improve early detection,
diagnosis, and treatment of breast cancer based on GP88. A&G’s Precision
Antibody™ service unit generates revenue to fund the diagnostic and drug development
effort by accelerating the creation of novel, customized antibodies for leading
pharmaceutical and biotechnology companies as well as federal laboratories.
A&G has raised $14 million of equity capital and is located in Columbia,
MD.
About Olympus
Olympus is a precision technology leader, creating innovative opto-digital
solutions in healthcare, life science and consumer electronics products. For
more information, visit http://www.olympus.co.jp/en/
For more information:
A&G Pharmaceutical
Michael Keefe
Vice President of Business Development
(410) 884-4100